Clinical Trials Logo

Filter by:
NCT ID: NCT03241108 Recruiting - Clinical trials for Rheumatoid Arthritis

Study of an Anti-TLR4 mAb in Rheumatoid Arthritis

Start date: May 10, 2017
Phase: Phase 2
Study type: Interventional

This is a Phase 2, PoC, randomized, placebo-controlled, double blind, international multicentre study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis

NCT ID: NCT03230292 Recruiting - Clinical trials for Chronic Plaque Psoriasis

This is a Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis.

Start date: July 3, 2017
Phase: Phase 2
Study type: Interventional

This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.

NCT ID: NCT03219957 Recruiting - Hepatitis C Clinical Trials

Study of AT-527 in Healthy and HCV-Infected Subjects

Start date: July 6, 2017
Phase: Phase 1
Study type: Interventional

This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV). In addition, the study will assess the antiviral activity of AT-527 in subjects infected with HCV.

NCT ID: NCT03139136 Recruiting - Clinical trials for Rheumatoid Arthritis

Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis

Start date: May 30, 2017
Phase: Phase 2
Study type: Interventional

Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments. MBS2320, the drug being tested in this trial, represents a new approach to treating RA, with the potential not only to reduce levels of inflammation but to also directly prevent bone damage.The aim of this project is to test the safety, tolerability and efficacy of MBS2320 in patients with RA in combination with an existing treatment, methotrexate.

NCT ID: NCT03077607 Recruiting - Clinical trials for Advanced Solid Tumors

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Start date: December 19, 2016
Phase: Phase 1
Study type: Interventional

This is a study in patients with advanced solid tumors for the investigation of P-gp inhibition and induction on the PK of talazoparib.

NCT ID: NCT03037489 Active, not recruiting - Clinical trials for Osteoarthritis, Knee

A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients

Start date: September 2016
Phase: Phase 2
Study type: Interventional

This is a multicentre, open-label, one-arm Phase II extension study to evaluate the safety and tolerability of MIV-711 in patients with knee joint osteoarthritis (OA).

NCT ID: NCT03032510 Active, not recruiting - Clinical trials for Complicated Urinary Tract Infections

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections

IGNITE3
Start date: January 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).

NCT ID: NCT03025542 Active, not recruiting - Clinical trials for Chronic Plaque Psoriasis

Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

NCT ID: NCT02983071 Recruiting - Breast Cancer Clinical Trials

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Start date: January 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study to investigate the potential clinical benefit of G1T38 as an oral therapy in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The study is an open-label design, consists of 2 parts: dose-finding portion (Part 1), and expansion portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 102 patients will be enrolled in the study.

NCT ID: NCT02983019 Completed - Influenza Clinical Trials

Treatment of Influenza in Routine Clinical Practice

FLU-EE
Start date: December 2013
Phase: N/A
Study type: Observational

This study evaluates the statistics of influenza and acute respiratory viral infections (ARVI) management in outpatient sites in Russia, Armenia, Moldova and Georgia (epidemiology: disease severity and bacterial exacerbations; patients demography; treatment duration and timelines; safety; quality of treatment) in routine clinical practice with focus on drug therapy and usage of interferons' inducers.